Phase 2 studies of cladribine combinations in indolent NHL
| Study . | Cladribine and other agent doses . | Other agents . | Histology, % . | Prior treatment, % . | OR, % . | CR, % . | Median duration, mo . | |
|---|---|---|---|---|---|---|---|---|
| Follicular . | Non . | |||||||
| Saven et al (1996)38 | A | Mitoxantrone | 57 | 43 | 100 | 70 | 22 | 5 (PR), 15 (CR) |
| Laurencet et al (1999)39 | B | Cyclophosphamide, prednisone | 0 | 100 | 42 | 88 | 22 | 12 (PR), 15 (CR) |
| Robak et al (1999)40 | C | Mitoxantrone, dexamethasone | 0 | 100 | 100 | 29 | 7 | > 6 |
| Rummel et al (2002)41 | D | Mitoxantrone | 51 | 49† | 32 | 90 | 44 | 24 |
| Van Den Neste et al (2004)37 | E | Cyclophosphamide | 26 | 74 | 100 | 51 | 14 | 11 |
| Robak et al (2004)42 | F | Rituximab | 12 | 88‡ | 100 | 69 | 15 | 7 |
| Robak et al (2006)43 | G | Rituximab, cyclophosphamide | 0 | 100§ | 100 | 71 | 11 | 11 |
| Laurencet et al (2007)44 | H | Cyclophosphamide, prednisone | 0 | 100 | 61 | 75 | 30 | 9 |
| Inwards et al (2008)45 (Study N0198) | I | Rituximab | 0 | 100‖ | 100 | 66 | 52 | 12 |
| Study . | Cladribine and other agent doses . | Other agents . | Histology, % . | Prior treatment, % . | OR, % . | CR, % . | Median duration, mo . | |
|---|---|---|---|---|---|---|---|---|
| Follicular . | Non . | |||||||
| Saven et al (1996)38 | A | Mitoxantrone | 57 | 43 | 100 | 70 | 22 | 5 (PR), 15 (CR) |
| Laurencet et al (1999)39 | B | Cyclophosphamide, prednisone | 0 | 100 | 42 | 88 | 22 | 12 (PR), 15 (CR) |
| Robak et al (1999)40 | C | Mitoxantrone, dexamethasone | 0 | 100 | 100 | 29 | 7 | > 6 |
| Rummel et al (2002)41 | D | Mitoxantrone | 51 | 49† | 32 | 90 | 44 | 24 |
| Van Den Neste et al (2004)37 | E | Cyclophosphamide | 26 | 74 | 100 | 51 | 14 | 11 |
| Robak et al (2004)42 | F | Rituximab | 12 | 88‡ | 100 | 69 | 15 | 7 |
| Robak et al (2006)43 | G | Rituximab, cyclophosphamide | 0 | 100§ | 100 | 71 | 11 | 11 |
| Laurencet et al (2007)44 | H | Cyclophosphamide, prednisone | 0 | 100 | 61 | 75 | 30 | 9 |
| Inwards et al (2008)45 (Study N0198) | I | Rituximab | 0 | 100‖ | 100 | 66 | 52 | 12 |
A indicates 0.1 mg/kg per day as continuous intravenous infusion for 7 days + mitoxantrone 5 mg/m2 intravenous day 1; B, 0.1 mg/kg per day subcutaneous bolus for 3 days; prednisone 40 mg/m2 PO for 5 days; cyclophosphamide 500 mg/m2 intravenous day 1; C, 0.12 mg/kg per day as 2-hour intravenous infusion for 5 consecutive days + mitoxantrone 10 mg/m2 + dexamethasone 20 mg/day intravenous/PO for 5 days; D, 5 mg/m2 2-hour intravenous infusion for 3 consecutive days + mitoxantrone 8 mg/m2 days 1 and 2, or 12 mg/m2 day 1 for first relapse; E, 5.6 mg/m2 per day for 3 days + cyclophosphamide 200 mg/m2 per day for 3 days; F, 0.12 mg/kg per day as 2-hour intravenous infusion for 5 consecutive days, days 2 to 6 + rituximab 375 mg/m2 as 6-hour intravenous infusion day 1; G, 0.12 mg/kg per day as 2-hour intravenous infusion for 3 consecutive days, days 2 to 4 + rituximab 375 mg/m2 as 6-hour intravenous infusion day 1 + cyclophosphamide 250 mg/m2 days 2 to 4; H, 0.1 mg/kg per day subcutaneous bolus injection for 5 days + prednisone 40 mg/m2 PO for 5 days + cyclophosphamide 500 mg/m2 intravenous day 1; and I, 5 mg/m2 2-hour intravenous infusion 5 consecutive days + rituximab 375 mg/m2 6-hour intravenous infusion day 1; and PR, partial response.
63% MCL.
65% CLL/small lymphocytic lymphoma.
17% MCL.
100% MCL.